IP Library Granted Patent US 8,987,239
Granted Patent B2
US 8,987,239 · App. 13/738,751 · Granted Mar 24, 2015

19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,987,239
App. No.
13/738,751
Granted
Mar 24, 2015
Kind
B2
Abstract

The 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSO 2 R, where R is hydrogen, C 1 -C 10 -alkyl, aryl or C 7 -C 20 -aralkyl, R 4 is hydrogen or halogen, and moreover either: R 6a , R 6b together form methylene or 1,2-ethanediyl or R 6a is hydrogen and R 6b is selected from the group comprising hydrogen, C 1 -C 10 -alkyl, C 2 -C 10 -alkenyl or C 2 -C 10 -alkynyl, and R 7 is selected from the group comprising hydrogen, C 1 -C 10 -alkyl, C 3 -C 6 -cycloalkyl, C 2 -C 10 -alkenyl or C 2 -C 10 -alkynyl, or: R 6a is hydrogen and R 6b and R 7 , together, denote a bond, an oxygen or form methylene, R 18 represents hydrogen or C 1 -C 3 -alkyl and in addition include their solvates, hydrates, stereoisomers and salts.

Claims (70)

1. 15α,16α-Methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone namely

17βHydroxy-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-ethyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-ethyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-vinyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-vinyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-cyclopropyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-cyclopropyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6-methylene-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6α-hydroxymethyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6α,7α,15α,16α-bismethylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6β,7β,15α,16α-bismethylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-15α,16α-methylene-19-nor-17α-pregna-4,6-dien-3-one-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-ethyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-ethyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-vinyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-vinyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-cyclopropyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-cyclopropyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6-methylene-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6α-hydroxymethyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6β-hydroxymethyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-6,6-(1,2-ethanediyl)-17β-hydroxy-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6 α,7α,15α,16α-bismethylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6 β,7β,15α,16α-bismethylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-15α,16α-methylene-19-nor-17α-pregna-4,6-diene-21-carboxylic acid γ-lactone;

17β-Hydroxy-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-ethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-ethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-vinyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-vinyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7α-cyclopropyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-7β-cyclopropyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6-methylene-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6α-hydroxymethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6β-hydroxymethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-en-3one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6α,7α,15α,16α-bismethylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-6β,7β,15α,16α-bismethylene-19-nor-17α-pregna-4-en-3-one-21-carboxylic acid γ-lactone;

17β-Hydroxy-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4,6-dien-3-one-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-methyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-methyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-ethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-ethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-vinyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-vinyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7α-cyclopropyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-7β-cyclopropyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6-methylene-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6α-hydroxymethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6β-hydroxymethyl-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-6,6-(1,2-ethanediyl)-17β-hydroxy-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6α,7α,15α,16α-bismethylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone;

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-6β,7β,15α,16α-bismethylene-19-nor-17α-pregna-4-ene-21-carboxylic acid γ-lactone; or

(E/Z)-3-(Hydroxyimino)-17β-hydroxy-18-methyl-15α,16α-methylene-19-nor-17α-pregna-4,6-diene-21-carboxylic acid γ-lactone.

2. A medicinal product containing at least one 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone derivative according to claim 1 and at least one pharmaceutically acceptable excipient.

3. The medicinal product as claimed in claim 2 , further comprising at least one estrogen.

4. The medicinal product as claimed in claim 3 , characterized in that the estrogen is ethinylestradiol.

5. The medicinal product as claimed in claim 3 , characterized in that the estrogen is a natural estrogen.

6. The medicinal product as claimed in claim 5 , characterized in that the natural estrogen is estradiol.

7. The medicinal product as claimed in claim 5 , characterized in that the natural estrogen is estradiolvalerate.

8. The medicinal product as claimed in claim 5 , characterized in that the natural estrogen is a conjugated estrogen.

9. A method of oral contraception comprising the step of administering a 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid γ-lactone derivative of claim 1 to a women in need thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2014
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033283/0004 →
CHANGE OF NAME Recorded Jul 1, 2014
From: BAYER SCHERING PHARMA AG
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033265/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: KLAR, ULRICH, DR.; KUHNKE, JOACHIM, DR.; BOHLMANN, ROLF, DR.; HÜBNER, JAN, DR.; RING, SVEN; FRENZEL, THOMAS, DR.; MENGES, FREDERIK, DR.; BORDEN, STEFFEN, DR.; MUHN, HANS-PETER, DR.; PRELLE, KATJA, DR.
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 033054/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: KLAR, ULRICH, DR.; KUHNKE, JOACHIM, DR.; BOHLMANN, ROLF, DR.; HÜBNER, JAN, DR.; RING, SVEN; FRENZEL, THOMAS, DR.; MENGES, FREDERIK, DR.; BORDEN, STEFFEN, DR.; MUHN, HANS-PETER, DR.; PRELLE, KATJA, DR.
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 033055/0043 →